Air Products & Chemicals, Inc. vs Medpace Holdings Inc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B), while Medpace Holdings Inc trades at $609.54 (market cap $16.90B). The key difference: Air Products & Chemicals, Inc. is far larger — about 4.1× Medpace Holdings Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| APD | MEDP | |
|---|---|---|
Market Cap | $68.88B | $16.90B |
Sector | Basic Materials | Technology |
52-Week High | $314.19 | $620.59 |
52-Week Low | $230.42 | $393.42 |
Enterprise Value | $86.06B | $16.52B |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.
Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.
Trailing returns across standard periods
Latest headlines on both assets
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →